| Description | MDK6204 is a selective inhibitor of CLK1 and CLK2. |
| Synonyms | CLK1/2 IN 2, CLK1/2IN2, CLK1/2-inhibitor-2, CLK1/2-IN-2, CLK1/2 inhibitor 2 |
| molecular weight | 360.41 |
| Molecular formula | C20H20N6O |
| CAS | 1005776-20-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Labrière C, Lozach O, Blairvacq M, Meijer L, Guillou C. Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. Eur J Med Chem. 2016 Nov 29;124:920-934. doi: 10.1016/j.ejmech.2016.08.069. Epub 2016 Aug 31. PubMed PMID: 27676471. 2. Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets. 2014 May;15(5):539-50. Review. PubMed PMID: 24568585. 3. Montes-Grajales D, Olivero-Verbel J. Computer-aided identification of novel protein targets of bisphenol A. Toxicol Lett. 2013 Oct 9;222(3):312-20. doi: 10.1016/j.toxlet.2013.08.010. Epub 2013 Aug 20. PubMed PMID: 23973438. 4. Wong R, Balachandran A, Mao AY, Dobson W, Gray-Owen S, Cochrane A. Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy. Retrovirology. 2011 Jun 17;8:47. doi: 10.1186/1742-4690-8-47. PubMed PMID: 21682887; PubMed Central PMCID: PMC3148977. |